Limits...
Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma.

Raja H, Snyder MR, Johnston PB, O'Neill BP, Caraballo JN, Balsanek JG, Peters BE, Decker PA, Pulido JS - PLoS ONE (2013)

Bottom Line: Here, we evaluate the utility of IL-10, IL-6 and IL-10/IL-6 for discriminating lymphoma from uveitis and report the effects of intraocular methotrexate and rituximab on aqueous cytokine levels in eyes with lymphoma.Using a receiver operating characteristic analysis to identify threshold values diagnostic for lymphoma, optimal sensitivity and specificity improved to 80.0% and 100%, respectively, for IL-10>7.025 pg/ml and 90.0% and 100.0%, respectively, for IL-10/IL-6>0.02718.In conclusion, optimal IL-10 and IL-10/IL-6 threshold values are associated with a diagnostic sensitivity ≥80% and specificity of 100%.

View Article: PubMed Central - PubMed

Affiliation: Mayo School of Graduate Medical Education, Mayo Clinic, Rochester, Minnesota, USA.

ABSTRACT
Intraocular cytokines are promising diagnostic biomarkers of vitreoretinal lymphoma. Here, we evaluate the utility of IL-10, IL-6 and IL-10/IL-6 for discriminating lymphoma from uveitis and report the effects of intraocular methotrexate and rituximab on aqueous cytokine levels in eyes with lymphoma. This is a retrospective case series including 10 patients with lymphoma and 7 patients with uveitis. Non-parametric Mann-Whitney analysis was performed to determine statistical significance of difference in interleukin levels between lymphoma and uveitis. Compared to eyes with uveitis, eyes with lymphoma had higher levels of IL-10 (U = 7.0; two-tailed p = 0.004) and IL-10/IL-6 (U = 6.0; two-tailed p = 0.003), whereas IL-6 levels were more elevated, although insignificant, in those patients with uveitis than in lymphoma (U = 15.0; two-tailed p = ns). Using a receiver operating characteristic analysis to identify threshold values diagnostic for lymphoma, optimal sensitivity and specificity improved to 80.0% and 100%, respectively, for IL-10>7.025 pg/ml and 90.0% and 100.0%, respectively, for IL-10/IL-6>0.02718. In patients in whom serial interleukin levels were available, regular intravitreal treatment with methotrexate and rituximab was associated with reduction in IL-10 levels over time. In conclusion, optimal IL-10 and IL-10/IL-6 threshold values are associated with a diagnostic sensitivity ≥80% and specificity of 100%. Therefore, these cytokines may serve as a useful adjunct in the diagnosis of lymphoma. While negative IL-10 and IL-10/IL-6 values do not exclude a diagnosis of lymphoma, elevated levels do appear to be consistent with lymphoma clinically. Moreover, elevated levels of IL-10 in the setting of a clinically quiet eye may point to impending disease recurrence. Lastly, once lymphoma is diagnosed, IL-10 levels can be monitored over time to assess disease activity and therapeutic response.

Show MeSH

Related in: MedlinePlus

IL concentrations and timing of intraocular treatment in a patient with unilateral lymphoma (Case 8).a) IL-10, b) IL-6, c) IL-10/IL-6. The vertical axis represents IL levels. Red arrows indicate intraocular treatment in the right eye, and blue diamonds indicate intraocular treatment in the left eye.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3672178&req=5

pone-0065627-g004: IL concentrations and timing of intraocular treatment in a patient with unilateral lymphoma (Case 8).a) IL-10, b) IL-6, c) IL-10/IL-6. The vertical axis represents IL levels. Red arrows indicate intraocular treatment in the right eye, and blue diamonds indicate intraocular treatment in the left eye.

Mentions: A 54-year-old man with systemic lymphoma underwent induction chemotherapy with high-dose MTX and six cycles of R-CHOP chemotherapy, followed by consolidation with BEAM conditioning and autologous stem cell transplant (SCT) in March 2009 to complete remission. In October 2008, he was diagnosed with vitreoretinal lymphoma and treated with periodic intraocular RTX with good clinical response. The patient developed relapse of ocular lymphoma in October 2010 and was treated with intraocular MTX, RTX, and corticosteroids. The IL-10 level was elevated in the right eye at the time of ocular relapse but declined to undetectable levels by March 2011 while receiving intraocular treatment. Interleukin-10 levels remained undetectable in the fellow eye. The patient has since been in complete remission. Interleukin-10, IL-6, and IL-10/IL-6 response to intravitreal treatment is displayed in graph form (Fig. 4a–c).


Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma.

Raja H, Snyder MR, Johnston PB, O'Neill BP, Caraballo JN, Balsanek JG, Peters BE, Decker PA, Pulido JS - PLoS ONE (2013)

IL concentrations and timing of intraocular treatment in a patient with unilateral lymphoma (Case 8).a) IL-10, b) IL-6, c) IL-10/IL-6. The vertical axis represents IL levels. Red arrows indicate intraocular treatment in the right eye, and blue diamonds indicate intraocular treatment in the left eye.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3672178&req=5

pone-0065627-g004: IL concentrations and timing of intraocular treatment in a patient with unilateral lymphoma (Case 8).a) IL-10, b) IL-6, c) IL-10/IL-6. The vertical axis represents IL levels. Red arrows indicate intraocular treatment in the right eye, and blue diamonds indicate intraocular treatment in the left eye.
Mentions: A 54-year-old man with systemic lymphoma underwent induction chemotherapy with high-dose MTX and six cycles of R-CHOP chemotherapy, followed by consolidation with BEAM conditioning and autologous stem cell transplant (SCT) in March 2009 to complete remission. In October 2008, he was diagnosed with vitreoretinal lymphoma and treated with periodic intraocular RTX with good clinical response. The patient developed relapse of ocular lymphoma in October 2010 and was treated with intraocular MTX, RTX, and corticosteroids. The IL-10 level was elevated in the right eye at the time of ocular relapse but declined to undetectable levels by March 2011 while receiving intraocular treatment. Interleukin-10 levels remained undetectable in the fellow eye. The patient has since been in complete remission. Interleukin-10, IL-6, and IL-10/IL-6 response to intravitreal treatment is displayed in graph form (Fig. 4a–c).

Bottom Line: Here, we evaluate the utility of IL-10, IL-6 and IL-10/IL-6 for discriminating lymphoma from uveitis and report the effects of intraocular methotrexate and rituximab on aqueous cytokine levels in eyes with lymphoma.Using a receiver operating characteristic analysis to identify threshold values diagnostic for lymphoma, optimal sensitivity and specificity improved to 80.0% and 100%, respectively, for IL-10>7.025 pg/ml and 90.0% and 100.0%, respectively, for IL-10/IL-6>0.02718.In conclusion, optimal IL-10 and IL-10/IL-6 threshold values are associated with a diagnostic sensitivity ≥80% and specificity of 100%.

View Article: PubMed Central - PubMed

Affiliation: Mayo School of Graduate Medical Education, Mayo Clinic, Rochester, Minnesota, USA.

ABSTRACT
Intraocular cytokines are promising diagnostic biomarkers of vitreoretinal lymphoma. Here, we evaluate the utility of IL-10, IL-6 and IL-10/IL-6 for discriminating lymphoma from uveitis and report the effects of intraocular methotrexate and rituximab on aqueous cytokine levels in eyes with lymphoma. This is a retrospective case series including 10 patients with lymphoma and 7 patients with uveitis. Non-parametric Mann-Whitney analysis was performed to determine statistical significance of difference in interleukin levels between lymphoma and uveitis. Compared to eyes with uveitis, eyes with lymphoma had higher levels of IL-10 (U = 7.0; two-tailed p = 0.004) and IL-10/IL-6 (U = 6.0; two-tailed p = 0.003), whereas IL-6 levels were more elevated, although insignificant, in those patients with uveitis than in lymphoma (U = 15.0; two-tailed p = ns). Using a receiver operating characteristic analysis to identify threshold values diagnostic for lymphoma, optimal sensitivity and specificity improved to 80.0% and 100%, respectively, for IL-10>7.025 pg/ml and 90.0% and 100.0%, respectively, for IL-10/IL-6>0.02718. In patients in whom serial interleukin levels were available, regular intravitreal treatment with methotrexate and rituximab was associated with reduction in IL-10 levels over time. In conclusion, optimal IL-10 and IL-10/IL-6 threshold values are associated with a diagnostic sensitivity ≥80% and specificity of 100%. Therefore, these cytokines may serve as a useful adjunct in the diagnosis of lymphoma. While negative IL-10 and IL-10/IL-6 values do not exclude a diagnosis of lymphoma, elevated levels do appear to be consistent with lymphoma clinically. Moreover, elevated levels of IL-10 in the setting of a clinically quiet eye may point to impending disease recurrence. Lastly, once lymphoma is diagnosed, IL-10 levels can be monitored over time to assess disease activity and therapeutic response.

Show MeSH
Related in: MedlinePlus